CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 1,087,843	$ 812,733
Marketable securities	1,104,309	596,847
Accounts receivable - trade, net	1,665,737	1,538,642
Accounts receivable from Sanofi	269,271	193,684
Accounts receivable from Bayer	267,937	242,014
Inventories	1,039,679	726,138
Prepaid expenses and other current assets	284,807	224,972
Total current assets	5,719,583	4,335,030
Marketable securities	1,873,569	1,486,494
Property, plant, and equipment, net	2,524,446	2,358,605
Deferred tax assets	562,818	506,291
Other noncurrent assets	125,197	77,866
Total assets	10,805,613	8,764,286
Current liabilities:
Accounts payable	172,361	178,183
Accrued expenses and other current liabilities	781,924	637,162
Total current liabilities	1,417,230	1,135,483
Capital and facility lease obligations	707,203	703,453
Other noncurrent liabilities	194,033	152,073
Total liabilities	2,937,313	2,620,208
Stockholders' equity:
Preferred Stock, $.01 par value; 30,000,000 shares authorized; issued and outstanding - none	0	0
Additional paid-in capital	3,841,174	3,512,833
Retained earnings	4,433,904	2,946,733
Accumulated other comprehensive (loss) income	(10,519)	640
Treasury Stock, at cost; 3,990,021 shares in 2018 and 3,763,868 shares in 2017	(396,371)	(316,240)
Total stockholders' equity	7,868,300	6,144,078
Total liabilities and stockholders' equity	10,805,613	8,764,286
Class A Stock
Stockholders' equity:
Common stock	2	2
Common Stock
Stockholders' equity:
Common stock	110	110
Sanofi
Current liabilities:
Deferred revenue, current	246,812	177,746
Deferred revenue, noncurrent	421,196	379,936
Other
Current liabilities:
Deferred revenue, current	216,133	142,392
Deferred revenue, noncurrent	$ 197,651	$ 249,263